Augmenting bispecific T-cell engager (BiTE) therapy for the treatment of Acute Myeloid Leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Ludwig-Maximilians-Universität, Dissertation, 2022
- Schlagwort
-
Therapeutics
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der Ludwig-Maximilians-Universität
- (wann)
-
2022
- Urheber
- Beteiligte Personen und Organisationen
-
Subklewe, Marion
- DOI
-
10.5282/edoc.29384
- URN
-
urn:nbn:de:bvb:19-293846
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brauchle, Bettina
- Subklewe, Marion
- Universitätsbibliothek der Ludwig-Maximilians-Universität
Entstanden
- 2022
Ähnliche Objekte (12)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia
The BiTE (Bispecific T‐Cell Engager) Platform: Development and Future Potential of a Targeted Immuno‐Oncology Therapy Across Tumor Types
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Aspects of the mode of action of bispecific T cell engager (BiTE) antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia
The BiTE (Bispecific T‐Cell Engager) Platform: Development and Future Potential of a Targeted Immuno‐Oncology Therapy Across Tumor Types
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Aspects of the mode of action of bispecific T cell engager (BiTE) antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia
The BiTE (Bispecific T‐Cell Engager) Platform: Development and Future Potential of a Targeted Immuno‐Oncology Therapy Across Tumor Types
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment
Aspects of the mode of action of bispecific T cell engager (BiTE) antibodies
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies